Logo image of BFRI

BIOFRONTERA INC (BFRI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BFRI - US09077D2099 - Common Stock

0.7956 USD
-0.03 (-3.51%)
Last: 1/12/2026, 5:20:00 PM
Fundamental Rating

2

BFRI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 190 industry peers in the Pharmaceuticals industry. BFRI has a bad profitability rating. Also its financial health evaluation is rather negative. BFRI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BFRI has reported negative net income.
In the past year BFRI has reported a negative cash flow from operations.
BFRI had negative earnings in each of the past 5 years.
BFRI had a negative operating cash flow in each of the past 5 years.
BFRI Yearly Net Income VS EBIT VS OCF VS FCFBFRI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

The Return On Assets of BFRI (-113.99%) is worse than 80.00% of its industry peers.
Industry RankSector Rank
ROA -113.99%
ROE N/A
ROIC N/A
ROA(3y)-51.23%
ROA(5y)-54.01%
ROE(3y)-274.43%
ROE(5y)-268.87%
ROIC(3y)N/A
ROIC(5y)N/A
BFRI Yearly ROA, ROE, ROICBFRI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

BFRI's Gross Margin of 64.41% is fine compared to the rest of the industry. BFRI outperforms 73.68% of its industry peers.
In the last couple of years the Gross Margin of BFRI has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for BFRI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.08%
GM growth 5Y-0.95%
BFRI Yearly Profit, Operating, Gross MarginsBFRI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

0

2. Health

2.1 Basic Checks

BFRI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BFRI has more shares outstanding
Compared to 5 years ago, BFRI has more shares outstanding
BFRI has a worse debt/assets ratio than last year.
BFRI Yearly Shares OutstandingBFRI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
BFRI Yearly Total Debt VS Total AssetsBFRI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

BFRI has an Altman-Z score of -13.03. This is a bad value and indicates that BFRI is not financially healthy and even has some risk of bankruptcy.
BFRI has a Altman-Z score of -13.03. This is in the lower half of the industry: BFRI underperforms 77.89% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.03
ROIC/WACCN/A
WACC18.07%
BFRI Yearly LT Debt VS Equity VS FCFBFRI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

A Current Ratio of 1.15 indicates that BFRI should not have too much problems paying its short term obligations.
With a Current ratio value of 1.15, BFRI is not doing good in the industry: 82.11% of the companies in the same industry are doing better.
BFRI has a Quick Ratio of 1.15. This is a bad value and indicates that BFRI is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.80, BFRI is not doing good in the industry: 82.11% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.15
Quick Ratio 0.8
BFRI Yearly Current Assets VS Current LiabilitesBFRI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

5

3. Growth

3.1 Past

BFRI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.55%, which is quite impressive.
The Revenue has been growing slightly by 5.11% in the past year.
Measured over the past years, BFRI shows a small growth in Revenue. The Revenue has been growing by 7.35% on average per year.
EPS 1Y (TTM)66.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.73%
Revenue 1Y (TTM)5.11%
Revenue growth 3Y15.69%
Revenue growth 5Y7.35%
Sales Q2Q%-22.46%

3.2 Future

BFRI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.61% yearly.
BFRI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.18% yearly.
EPS Next Y62.98%
EPS Next 2Y40.29%
EPS Next 3Y26.61%
EPS Next 5YN/A
Revenue Next Year2.11%
Revenue Next 2Y6.44%
Revenue Next 3Y9.85%
Revenue Next 5Y14.18%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BFRI Yearly Revenue VS EstimatesBFRI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M 100M
BFRI Yearly EPS VS EstimatesBFRI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BFRI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BFRI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BFRI Price Earnings VS Forward Price EarningsBFRI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BFRI Per share dataBFRI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

BFRI's earnings are expected to grow with 26.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.29%
EPS Next 3Y26.61%

More info and screens

0

5. Dividend

5.1 Amount

BFRI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BIOFRONTERA INC

NASDAQ:BFRI (1/12/2026, 5:20:00 PM)

0.7956

-0.03 (-3.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-19 2026-03-19/amc
Inst Owners17.06%
Inst Owner Change0%
Ins Owners4.7%
Ins Owner Change27.04%
Market Cap9.27M
Revenue(TTM)37.16M
Net Income(TTM)-17.57M
Analysts82.5
Price Target6.12 (669.23%)
Short Float %0.55%
Short Ratio0.37
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-18.93%
Min EPS beat(2)-33.05%
Max EPS beat(2)-4.8%
EPS beat(4)0
Avg EPS beat(4)-258.14%
Min EPS beat(4)-880.39%
Max EPS beat(4)-4.8%
EPS beat(8)1
Avg EPS beat(8)-142.95%
EPS beat(12)1
Avg EPS beat(12)-106.93%
EPS beat(16)4
Avg EPS beat(16)-70.42%
Revenue beat(2)1
Avg Revenue beat(2)2.27%
Min Revenue beat(2)-2.13%
Max Revenue beat(2)6.66%
Revenue beat(4)1
Avg Revenue beat(4)-7.73%
Min Revenue beat(4)-20.19%
Max Revenue beat(4)6.66%
Revenue beat(8)1
Avg Revenue beat(8)-10.92%
Revenue beat(12)2
Avg Revenue beat(12)-8.47%
Revenue beat(16)2
Avg Revenue beat(16)-7.07%
PT rev (1m)0%
PT rev (3m)-7.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)57.89%
EPS NY rev (1m)0%
EPS NY rev (3m)-12.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)10.73%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.25
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.91
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-1.03
FCFYN/A
OCF(TTM)-1.03
OCFYN/A
SpS3.19
BVpS-0.22
TBVpS-0.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -113.99%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.41%
FCFM N/A
ROA(3y)-51.23%
ROA(5y)-54.01%
ROE(3y)-274.43%
ROE(5y)-268.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.08%
GM growth 5Y-0.95%
F-Score3
Asset Turnover2.41
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -0.93%
Cap/Sales 0.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.15
Quick Ratio 0.8
Altman-Z -13.03
F-Score3
WACC18.07%
ROIC/WACCN/A
Cap/Depr(3y)7.65%
Cap/Depr(5y)4.96%
Cap/Sales(3y)0.1%
Cap/Sales(5y)0.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.73%
EPS Next Y62.98%
EPS Next 2Y40.29%
EPS Next 3Y26.61%
EPS Next 5YN/A
Revenue 1Y (TTM)5.11%
Revenue growth 3Y15.69%
Revenue growth 5Y7.35%
Sales Q2Q%-22.46%
Revenue Next Year2.11%
Revenue Next 2Y6.44%
Revenue Next 3Y9.85%
Revenue Next 5Y14.18%
EBIT growth 1Y8.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year56.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.61%
OCF growth 3YN/A
OCF growth 5YN/A

BIOFRONTERA INC / BFRI FAQ

What is the fundamental rating for BFRI stock?

ChartMill assigns a fundamental rating of 2 / 10 to BFRI.


What is the valuation status for BFRI stock?

ChartMill assigns a valuation rating of 1 / 10 to BIOFRONTERA INC (BFRI). This can be considered as Overvalued.


What is the profitability of BFRI stock?

BIOFRONTERA INC (BFRI) has a profitability rating of 1 / 10.


What is the expected EPS growth for BIOFRONTERA INC (BFRI) stock?

The Earnings per Share (EPS) of BIOFRONTERA INC (BFRI) is expected to grow by 62.98% in the next year.